BTIG Research Reiterates “Buy” Rating for Tiziana Life Sciences (NASDAQ:TLSA)

Tiziana Life Sciences (NASDAQ:TLSA)‘s stock had its “buy” rating reaffirmed by BTIG Research in a research report issued on Tuesday, Benzinga reports.

A number of other research analysts have also recently weighed in on the stock. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tiziana Life Sciences in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Tiziana Life Sciences Stock Performance

Shares of TLSA opened at $1.05 on Tuesday. Tiziana Life Sciences has a 12-month low of $0.76 and a 12-month high of $2.35. The company has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.19.

Insider Activity

In other news, CEO Ivor Elrifi purchased 237,616 shares of the stock in a transaction dated Wednesday, August 5th. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the completion of the acquisition, the chief executive officer directly owned 4,793,684 shares in the company, valued at $4,793,684. This represents a 5.22% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have bought 988,423 shares of company stock worth $985,909. 39.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently bought a new position in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 323,240 shares of the company’s stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned 0.25% of Tiziana Life Sciences as of its most recent filing with the Securities & Exchange Commission.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.